Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023

    Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

    May 23, 2023

    Israeli biotech phenom puts death knell on cancer

    May 22, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Manappuram Finance, Rossari Biotech shares trade ex-dividend today

      May 24, 2023

      Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

      May 23, 2023

      Israeli biotech phenom puts death knell on cancer

      May 22, 2023

      Six Norwegian companies leading the country’s biotech scene

      May 19, 2023

      Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data

      May 18, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»A series of mega-blockbuster drugs are on the horizon. How to invest in the trend
    Bio Technology

    A series of mega-blockbuster drugs are on the horizon. How to invest in the trend

    yourbiotechBy yourbiotechOctober 10, 2022No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email
    • The whooping cough vaccine is the first shot the FDA has approved specifically for use during pregnancy to protect newborns.
    • The vaccine, called Boostrix, is made by GlaxoSmithKline.
    • Pertussis, more commonly known as whooping cough, is a highly contagious respiratory disease that can lead to serious health complications in babies.
    • Infants younger than two months are not old enough to receive protection through the normal childhood vaccination series.

    The Food and Drug Administration on Friday approved a vaccine for use in the third trimester of pregnancy to prevent whooping cough in newborn infants.

    The vaccine, called Boostrix, is made by GlaxoSmithKline. It is the first vaccine the FDA has approved to prevent a disease in young infants by giving the shot to their mothers during pregnancy, said Dr. Peter Marks, the agency’s chief vaccine official.

    The vaccine, which is administered as a single dose, was 78% effective in preventing whooping cough in newborns when given to mothers during the third trimester, according to data evaluated by the FDA. No side effects on the pregnancy, fetus or newborn were observed.

    The most common side effects for people who receive the vaccine are pain at the injection site, headache and fatigue.

    Pertussis, more commonly known as whooping cough, is a highly contagious respiratory disease that can lead to serious health complications in babies. Infants younger than two months are not old enough to receive protection through the normal childhood vaccination series for the disease.

    The vaccine allows mothers to protect their newborns by getting the shot while they are pregnant. While whooping cough can affect all age groups, most cases of hospitalization and death occur infants younger than two months old, according to FDA.

    The FDA had previously approved Boostrix for use during pregnancy to protect the mother against disease, but had not cleared it specifically to prevent whooping cough in newborns. The vaccine was first approved in 2005 to protect people ages 10 to 18 years old against whooping cough and then later for everyone ages 19 and older.

    CNBC Health & Science

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleAsia’s pharma hub Baddi has no drug-testing lab
    Next Article Maiden Pharma may lose import-export licence over cough syrup controversy in Gambia
    yourbiotech
    • Website

    Related Posts

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023

    Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

    May 23, 2023

    Israeli biotech phenom puts death knell on cancer

    May 22, 2023

    Six Norwegian companies leading the country’s biotech scene

    May 19, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.